Targeted radiation therapy shows promise for Tough-to-Treat prostate cancer
NCT ID NCT05219500
Summary
This study is testing a new targeted radiation treatment called FPI-2265 for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The treatment delivers radiation directly to cancer cells using a molecule that seeks out a protein on the tumor. Researchers are checking if the treatment safely reduces prostate-specific antigen (PSA) levels and controls the cancer's growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Excel Diagnostics and Nuclear Oncology Center
Houston, Texas, 77042, United States
-
XCancer Omaha/Urology Cancer Center
Omaha, Nebraska, 68130, United States
Conditions
Explore the condition pages connected to this study.